Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker.
Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker.
复制标题
DOI：
10.3389/fimmu.2020.631299
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Lamot L
中科院分区：
文献类型：
--
作者：
Sorić Hosman I;Kos I;Lamot L
血清淀粉样蛋白A （SAA）是一种急性期蛋白，对炎症性风湿病（IRD）患者具有重要意义。最近的发现证实了SAA在IRD发病机制中的核心作用，包括它参与炎症小体级联的激活和产生白细胞介素17的T辅助细胞的募集。SAA在IRD中的临床应用最初是在近半个世纪前评估的。从最初的研究结果来看，SAA显然可以用于评估类风湿关节炎和继发性淀粉样变性患者的疾病严重程度和监测疾病活动。然而，成本效益和更容易应用的标记物，如c反应蛋白（CRP）和红细胞沉降率（ESR），在临床实践中压倒了它的应用。根据新出现的证据，SAA已被认为是广泛的IRD中更敏感的生物标志物，特别是在亚临床炎症的情况下。此外，越来越多的研究证实SAA在预测和监测IRD患者对生物免疫治疗的反应方面优于许多其他生物标志物。关于SAA作用的科学发现，以及最近发展的蛋白质组学技术将SAA及其同型物描述为各种IRD中最敏感的生物标志物，正在鼓励其临床应用的复兴。最后，最近的研究结果表明，SAA是2019年严重冠状病毒病（COVID-19）的生物标志物。这篇综述的目的是讨论SAA涉及的免疫系统网络，重点是与IRD相关的机制，以及SAA作为各种IRD的生物标志物的用途。因此，通过广泛的PubMed和Scopus数据库搜索，收集了一百多篇原始论文。这些最近出现的见解有望导致更好地管理IRD患者，甚至可能激发以SAA为靶点的新治疗策略的发展。
Serum amyloid A (SAA) is an acute phase protein with a significant importance for patients with inflammatory rheumatic diseases (IRD). The central role of SAA in pathogenesis of IRD has been confirmed by recent discoveries, including its involvement in the activation of the inflammasome cascade and recruitment of interleukin 17 producing T helper cells. Clinical utility of SAA in IRD was originally evaluated nearly half a century ago. From the first findings, it was clear that SAA could be used for evaluating disease severity and monitoring disease activity in patients with rheumatoid arthritis and secondary amyloidosis. However, cost-effective and more easily applicable markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), overwhelmed its use in clinical practice. In the light of emerging evidences, SAA has been discerned as a more sensitive biomarker in a wide spectrum of IRD, especially in case of subclinical inflammation. Furthermore, a growing number of studies are confirming the advantages of SAA over many other biomarkers in predicting and monitoring response to biological immunotherapy in IRD patients. Arising scientific discoveries regarding the role of SAA, as well as delineating SAA and its isoforms as the most sensitive biomarkers in various IRD by recently developing proteomic techniques are encouraging the revival of its clinical use. Finally, the most recent findings have shown that SAA is a biomarker of severe Coronavirus disease 2019 (COVID-19). The aim of this review is to discuss the SAA-involving immune system network with emphasis on mechanisms relevant for IRD, as well as usefulness of SAA as a biomarker in various IRD. Therefore, over a hundred original papers were collected through an extensive PubMed and Scopus databases search. These recently arising insights will hopefully lead to a better management of IRD patients and might even inspire the development of new therapeutic strategies with SAA as a target.
登录
查看更多内容
影响因子：
3.7
作者：
Centola M;Cavet G;Shen Y;Ramanujan S;Knowlton N;Swan KA;Turner M;Sutton C;Smith DR;Haney DJ;Chernoff D;Hesterberg LK;Carulli JP;Taylor PC;Shadick NA;Weinblatt ME;Curtis JR
通讯作者：
Curtis JR
影响因子：
4.6
作者：
Cantarini, L.;Pucino, V.;Matarese, G.
通讯作者：
Matarese, G.
影响因子：
--
作者：
BENSON, MD;COHEN, AS
通讯作者：
COHEN, AS
影响因子：
4.4
作者：
Boyd, T. A.;Eastman, P. S.;Kavanaugh, A.
通讯作者：
Kavanaugh, A.
影响因子：
27.4
作者：
CHAMBERS, RE;MACFARLANE, DG;DIEPPE, PA
通讯作者：
DIEPPE, PA